Tibor Borsós

Tibor Borsós's AcademicInfluence.com Rankings

Tibor Borsós

Biology

#8999

World Rank

#12153

Historical Rank

Molecular Biology

#1186

World Rank

#1212

Historical Rank

Neuroscience

#1293

World Rank

#1338

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Tibor Borsós Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Tibor Borsós's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Molecular Basis of Complement Action (1970) (425)
Complement Fixation on Cell Surfaces by 19S and 7S Antibodies (1965) (305)
BCG and cancer (first of two parts). (2010) (259)
BCG and cancer. (1974) (212)
Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement. (1967) (186)
Tumor-specific antigen solubilized by hypertonic potassium chloride. (1971) (181)
Hemolysin titration based on fixation of the activated first component of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte. (1965) (163)
CHROMATOGRAPHIC SEPARATION OF THE FIRST COMPONENT OF COMPLEMENT AND ITS ASSAY ON A MOLECULAR BASIS. (1963) (156)
Lesions in Erythrocyte Membranes Caused by Immune Hæmolysis (1964) (155)
125I protein A: applications to the quantitative determination of fluid phase and cell-bound IgG. (1977) (129)
Production, growth and properties of ultrafine atmospheric aerosol particles in an urban environment (2010) (117)
Neutralization of sensitized virus by purified components of complement. (1970) (111)
EFFECTS OF LOW IONIC STRENGTH ON IMMUNE HEMOLYSIS. (1963) (107)
Antigenicity of a new diethylnitrosamine-induced transplantable guinea pig hepatoma: pathology and formation of ascites variant. (1968) (106)
C'-1 fixation by human isoagglutinins: fixation of C'-1 by gamma-G and gamma-M but not by gamma-A antibody. (1966) (92)
Tumor-graft rejection in syngeneic guinea pigs: evidence for a two-step mechanism. (1970) (87)
Neutralization of Sensitized Virus by the Fourth Component of Complement (1969) (79)
THE INTERACTION BETWEEN CARRAGEENAN AND THE FIRST COMPONENT OF COMPLEMENT. (1965) (77)
Antigenic specificity of hepatomas induced in strain-2 guinea pigs by diethylnitrosamine. (1969) (77)
Studies on the Second Component of Complement. I. The Reaction between EAC'1,4 and C'2: Evidence on the Single Site Mechanism of Immune Hemolysis and Determination of C'2 on a Molecular Basis. (1961) (72)
Studies on the interaction between protein A and immunoglobulin G. I. Effect of protein A on the functional activity of IgG. (1978) (69)
SYNTHESIS OF THE FIRST COMPONENT OF HUMAN COMPLEMENT IN VITRO (1968) (67)
Brief communication: antigenic relationship between Mycobacterium bovis (BCG) and a guinea pig hepatoma. (1973) (62)
Tumor-Specific Antigens Detected by Inhibition of Macrophage Migration (1969) (61)
Studies on the interaction between protein A and immunoglobulin G. II. Composition and activity of complexes formed between protein A and IgG. (1978) (60)
DIFFERENCES IN SERUM COMPLEMENT ACTIVITY AMONG INBRED STRAINS OF MICE. (1964) (55)
ACTION OF THE FIRST COMPONENT OF COMPLEMENT. ACTIVITATION OF C'1 TO C'1A IN THE HEMOLYTIC SYSTEM. (1964) (53)
Studies on the terminal stages of immune hemolysis. VI. Osmotic blockers of differing Stokes' radii detect complement-induced transmembrane channels of differing size. (1979) (53)
Correlation between the ability of tumor cells to resist humoral immune attack and their ability to synthesize lipid. (1978) (50)
MOUSE COMPLEMENT: THE EFFECT OF SEX HORMONES AND CASTRATION ON TWO OF THE LATE-ACTING COMPONENTS (1967) (49)
Production of the second (C2) and fourth (C4) components of guinea pig complement by single peritoneal cells: evidence that one cell may produce both components. (1972) (47)
Activation of the first component of complement evidence for an internal activation step. (1972) (45)
STUDIES ON THE TERMINAL STEPS OF IMMUNE HEMOLYSIS. I. INHIBITION BY TRISODIUM ETHYLENEDIAMINETETRAACETATE (EDTA). (1964) (45)
Lysis of tumor cells by antibody and complement. 1. Lack of correlation between antigen content and lytic susceptibility. (1973) (43)
Distinction between fixation of C1 and the activation of complement by natural IgM anti-hapten antibody: effect of cell surface hapten density. (1981) (42)
Chemotherapeutic drugs increase killing of tumor cells by antibody and complement. (1975) (42)
Detection of bound C3 by a new immunochemical methods. (1971) (42)
Biological Activity of Aggregated γ-Globulin IV. Mechanism of Complement Fixation (1961) (42)
Two-step mechanism of tumor graft rejection in syngeneic guinea pigs. II. Initiation of reaction by a cell fraction containing lymphocytes and neutrophils. (1970) (42)
Physical properties, chemical composition, sources, spatial distribution and sinks of indoor aerosol particles in a university lecture hall (2013) (41)
Comparison of particulate number concentrations in three Central European capital cities. (2012) (41)
Comparative study of ultrafine atmospheric aerosol within a city (2014) (41)
Detection of Antigens of a New Diethylnitrosamine-Induced Transplantable Hepatoma by Delayed Hypersensitivity (1968) (37)
Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. II. Clustering of effective C42 complexes at individual hemolytic sites. (1971) (36)
In vitro synthesis of the first component of complement by guinea pig small intestine. (1966) (36)
The C'la fixation and transfer test: examples of its applicability to the detection and enumeration of antigens and antibodies at cell surfaces. (1968) (35)
Regression of established tumors and induction of tumor immunity by intratumor chemotherapy. (1976) (35)
Ultracentrifugation of the first component of complement: effects of ionic strength. (1968) (35)
Synthesis of the first component of guinea pig complement by columnar epithelial cells of the small intestine. (1968) (35)
STUDIES ON THE TERMINAL STEPS OF IMMUNE HEMOLYSIS. II. RESOLUTION OF THE E TRANSFORMATION REACTION INTO MULTIPLE STEPS. (1964) (34)
Lysis of tumor cells by antibody and complement. II. Lack of correlation between amount of C4 and C3 fixed and cell lysis. (1975) (33)
Systemic transfer of tumor immunity: delayed hypersensitivity and suppression of tumor growth. (1970) (33)
Immunochemical detection of tumor-specific and embryonic antigens of diethylnitrosamine-induced guinea pig tumors. (1973) (32)
INDUCTION OF TUMOR IMMUNITY BY INTRATUMORAL CHEMOTHERAPY (1976) (32)
Enhancing effect by metabolic inhibitors on the killing of tumor cells by antibody and complement. (1975) (31)
Titration of the first component of complement on a molecular basis: suitability of IgM and unsuitability of IgG hemolysins as sensitizer. (1969) (30)
Lysis of tumor cells by antibody and complement. VII. Complement-dependent 86Rb release--a nonlethal event? (1976) (30)
Brief Communication: Effect of Metabolic Inhibitors on Killing of Tumor Cells by Antibody and Complement (1974) (30)
Purification of the first component of complement by zonal ultracentrifugation. (1969) (29)
Complement and Hemolysis. (1963) (29)
Distinction between C8-mediated and C8/C9-mediated hemolysis on the basis of independent 86Rb and hemoglobin release. (1980) (29)
Studies on the terminal stages of immune hemolysis. III. Distinction between the insertion of C9 and the formation of a transmembrane channel. (1978) (29)
On the Hemolytic Activity of Mouse Complement.∗ (1961) (28)
ESTIMATION OF MOLECULAR SIZE OF COMPLEMENT COMPONENTS BY SEPHADEX CHROMATOGRAPHY. (1965) (28)
Studies on the terminal stages of immune hemolysis. V. Evidence that not all complement-produced transmembrane channels are equal. (1979) (28)
Forssman antigen and antibody: preparation of water soluble antigen and measurement of antibody concentration by precipitin analysis, by C'1a fixation and by hemolytic activity. (1966) (28)
Stimulation of the synthesis and release of lipids in tumor cells under attack by antibody and C. (1978) (26)
HETEROGENEITY OF RABBIT IGM ANTIBODY AS DETECTED BY C'1a FIXATION (1968) (26)
Studies on the terminal stages of antibody-complement-mediated killing of a tumor cell. II. Inhibition of transformation of T to dead cells by 3'5' cAMP. (1976) (26)
The first component of complement in serum: evidence for a hitherto unrecognized factor in C1 necessary for internal activation. (1973) (26)
Molecular interactions of cells with antibody and complement: influence of metabolic and physical properties of the target on the outcome of humoral immune attack. (1978) (25)
A solid-phase immunoassay for human immunoglobulin E: use of 125I-labeled protein A as the tracer. (1979) (25)
Identification of lipids associated with the ability of tumor cells to resist humoral immune attack. (1978) (25)
Studies on the terminal stages of immune hemolysis. IV. Effect of metal salts. (1979) (24)
Effect of inhibiting DNA, RNA, and protein synthesis of tumor cells on their susceptibility to killing by antibody and complement. (1977) (24)
Studies on the Second Component of Complement. II. The Nature of the Decay of EAC'1,4,2. (1961) (24)
Quantitative comparison of techniques used to measure complement-mediated cytotoxicity of nucleated cells. (1975) (24)
Heat-labile, complement-like factor(s) of animal sera prevent(s) HIV-1 infectivity in vitro. (1990) (24)
Immunotherapy of Cancer: An Experimental Model in Syngeneic Guinea Pigs (1970) (24)
Lysis of hapten-labeled cells by anti-hapten IgG and complement: effect of cell surface hapten density. (1982) (24)
Immune Surveillance Revisited (1974) (23)
Identification of lipids synthesized and released by tumor cells under attack by antibody and complement. (1978) (23)
Separation of Components of Guinea Pig Complement by Chromatography.∗ (1959) (23)
Lysis of tumor cells by antibody and complement. VI. Enhanced killing of enzyme-pretreated tumor cells. (1975) (22)
Structural characteristics of hemolytic antibodies as determined by the effects of ionizing radiation. (1967) (22)
Detection of endotoxin in commercial L-asparaginase preparations by complement fixation and separation by chromatography. (1972) (22)
Immunotherapy of an intramuscular tumor in strain-2 guinea pigs: prevention of tumor growth by intradermal immunization and by systemic transfer of tumor immunity. (1970) (22)
Efficiency of activation of complement by anti-hapten antibodies at the red cell surface: effect of patchy vs random distribution of hapten. (1985) (21)
Binding and activation of C4 and C3 on the red cell surface by non-complement enzymes. (1988) (20)
Mouse Complement: Influence of Sex Hormones on Its Activity (1966) (20)
Reversible loss of activity of the first component of complement (C'1) as a function of ionic strength. (1968) (20)
Detection of antigens of a new diethylnitrosamine-induced transplantable hepatoma by delayed hypersensitivity. (1969) (20)
Interaction between components of the human classical complement pathway and immobilized Cibacron Blue F3GA. (1979) (19)
Studies on immune factors occurring in sera of chickens against the crithidia stage of Trypanosoma cruzi. (1959) (18)
Studies on the Second Component of Complement. III. Separation of the Second Component from Guinea Pig Serum by Chromatography on Cellulose Derivatives. (1961) (18)
Analysis of the colloid osmotic step of complement-mediated immune hemolysis. (1980) (18)
The terminal stages of immune hemolysis--a brief review. (1980) (17)
Abrogation of passively transferred tumor immunity in vivo by antigenically related tumor cells. (1971) (17)
Efficiency of the First Component of Complement (C'1) in the Hemolytic Reaction (1967) (17)
Cold-reacting antibodies: the enhancement of antibody fixation by the first component of complement (C'1a). (1968) (17)
Ontogeny of the first component of sheep complement. (1968) (16)
Correlation between the ability of tumor cells to incorporate specific fatty acids and their sensitivity to killing by a specific antibody plus guinea pig complement. (1978) (16)
Complement Fixation (1965) (16)
Complement research. Fundamental and applied. (1966) (15)
Synthesis of the second component of guinea pig complement in vitro. (1971) (15)
Guinea pig leukemia L2C: characterization of chromosomes and attempts to demonstrate antigenicity. (1970) (15)
Binding and activation of C1 by cell bound IgG: activation depends on cell surface hapten density. (1983) (14)
Properties of tumor-specific antigen solubilized by hypertonic potassium chloride. (1972) (14)
Inhibition of antibody-complement-mediated killing of tumor cells by hormones. (1976) (14)
Resolution of the first component of guinea pig complement into three subunits, Clq, Clr and Cls, and their hybridization with human Cl subunits. (1972) (14)
C4 does not bind to human and rabbit IgM during activation of the classical complement pathway on the red cell. (1982) (14)
Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. I. Functional differences among C4 sites on cell surfaces. (1970) (13)
Isoelectric focusing of human and guinea-pig C2: polymorphism of guinea-pig C2. (1970) (12)
Lysis of tumor cells by antibody and complement. III. Lack of correlation between antigen movement and cell lysis. (1975) (12)
Brief Communication: Accelerated Development of Benzo [a] pyrene-Induced Skin Tumors in Mice Treated With Pyran Copolymer (1974) (12)
Cytotoxic action of antiserum and complement: quantification with a colony inhibition method. (1971) (12)
Isolation and Characterization of a Factor from Human and Guinea Pig Serum That Accelerates the Decay of SAC142 (1971) (12)
Randomized clinical study on intratumoral BCG-cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region (1981) (12)
Immune complex mediated activation of the classical complement pathway. (1989) (12)
Effect of metabolic inhibitors on the ability of tumor cells to express antigen and bind complement components C4 and C3. (1975) (12)
Absence of neutralization of Rous sarcoma virus by antinormal-chicken-embryo serum and complement. (1958) (11)
Synthesis of specific lipids associated with the hormone-induced resistance of tumor cells to humoral immune killing. (1979) (11)
Natural antibodies in mammalian sera to folinic acid and methotrexate. (1981) (10)
Naturally soluble tumor antigens from guinea pig hepatomas: isolation and partial characterization. (1976) (10)
Studies on the terminal stages of antibody-complement-mediated killing of a tumor cell. I. Evidence for the existence of an intermediate, T. (1976) (10)
Tumor-specific antigens: detection by local transfer of delayed skin hypersensitivity. (1969) (10)
Immunoassay of antigens and haptens by inhibition of passive immune hemolysis. (1980) (10)
Forssman antigen content of guinea pig hepatomas induced by diethylnitrosamine: a quantitative approach to the search for tumor-specific antibodies. (1966) (10)
Complement-dependent cytotoxic antitumor antibody. I. Immunoglobulin class determined by interaction with protein A or concanavalin A. (1978) (10)
Time-resolved number concentrations and size distribution of aerosol particles in an urban road tunnel (2011) (10)
Effect of concanavalin A on the classical complement pathway. (1977) (10)
Mouse monoclonal antibodies at the red cell surface--II. Effect of hapten density on complement fixation and activation. (1985) (9)
Differences in cell-bound C8 sites on chicken erythrocytes measured by their reactivity with guinea pig and human C9. (1980) (9)
Quantitation of hemorrhagic lesions in the chick embryo produced by the Rous tumor virus. (1957) (9)
A novel way of relating the structure of Cl1 to the hemolytic activity of the first component of complement. (1980) (9)
C′1 Fixation by Human Isoagglutinins: Fixation of C′1 by γG and γM but Not by γA Antibody (1966) (9)
Presence of A-type and absence of C-type virus particles in a chemically induced guinea pig hepatoma. (1974) (9)
Killing of Nucleated Cells by Antibody and Complement (1977) (8)
Persistence of immunoglobulin and complement components C4 and C3 bound to guinea pig tumor cells. (1976) (8)
Plasma therapy of primary rat mammary carcinoma: dependence of consumption of C3 during absorption of plasma with sepharose derivatives on the anticoagulant. (1985) (8)
Heterogeneity in the size and stability of transmembrane channels produced by whole complement. (1981) (8)
Evidence for a temperature-dependent and temperature-independent pathway in the generation of complement-mediated transmembrane channels. (1980) (8)
Lack of Correlation Between Antigen Content and Lytic Susceptibility of Tumor Cells (1973) (7)
Activation of human C1: analysis with Western blotting reveals slow self-activation. (1987) (7)
Serum Gamma Globulin and Trypanosoma cruzi Agglutinin in Embryonic, “Normal'”and Germ-Free Chickens.∗ (1958) (7)
Antigenic relationships between the first component (Cl) of human and guinea pig complement. (1970) (7)
Pathogenesis of rous sarcoma virus in the chick embryo with particular reference to vascular lesions (1968) (7)
Immunochemical quantitation of cell bound C4. (1974) (7)
Biosynthesis of the second and fourth components of complement: inhibition in vitro by chemical carcinogens. (1974) (7)
Immunochemical quantitaion of the third component of guinea pig complement in fluid phase and bound to cell surfaces. (1975) (6)
Activation of hemolytic complement by mouse monoclonal IgG1 antibody: comparison with rabbit IgG. (1985) (6)
Studies on the terminal stages of antibody-complement mediated killing of a tumor cell. III. Effect of membrane active agents. (1976) (6)
Effect of metabolic inhibitors on killing of tumor cells by antibody and complement. (1974) (6)
Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. IV. Formation of EAC42 by treatment of C2 with trypsin in the presence of EAC4. (1972) (6)
Immunoglobulin Classes and Complement-Fixing Activity (1971) (6)
Effect of C3 inactivator on bound C3 antigen. (1972) (6)
Quantification of complement fixation by the C1 fixation and C1 fixation and transfer tests. (1981) (5)
Mathematical analysis of the reaction of EAC1-8 with C9: identification of parameters defining conditions for molecular titration. (1980) (5)
Lack of binding of C3 to IgG antibodies during the activation of the classical complement pathway on the red cell. (1984) (5)
Inactivation of complement by L-asparaginase preparations not correlated with enzyme content. (1972) (5)
A new complement fixation test: Enumeration of antibodies at cell surfaces on a molecular basis (1966) (5)
Effect of lectins on the hemolytic activity of complement components. (1978) (5)
Kinetics of hormone-induced tumor cell resistance to killing by antibody and complement. (1977) (5)
Detection of complement-dependent antibody to tumor cells in sera of strain-2 guinea pigs cured of their tumors by BCG Treatment. (1976) (4)
Effect of concanavalin A on the killing of tumor cells by antibody and complement. (1977) (4)
Complement and Hemolytic Antibody: Changes in Their Activity Induced by Mercaptoethanol (1965) (4)
Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. 3. The hemolytic efficiency of human and guinea pig C2 and C4. (1971) (4)
Effect of concanavalin A on the functional activity of hemolytic antibody. (1977) (4)
1,10-Phenanthroline mediated hemolysis--evidence that 1,10-phenanthroline does not substitute specifically for C9. (1979) (4)
Cell-bound C4b resists reduction by reducing agents: analysis by chain structure and by hemolytic activity. (1983) (4)
Antigenic loss in a transplantable, chemically induced leukemia of C57BL/6 mice. (1970) (4)
Regression of established oral tumors after intralesional injection of living BCG OR BCG cell walls (1979) (4)
Metabolic requirements for hormone-induced resistance to antibody-complement mediated killing of tumor cells. (1977) (4)
Anti-hapten IgG antibodies bound to cell surface hapten: anti-IgG antibody prevents dissociation as measured with fluid phase hapten. (1986) (4)
Hemolytic efficiency of cell-bound IgM: evidence that IgM-C1 complexes activate C4 molecules not hemolytic with homologous C2--C9. (1982) (3)
Serotherapy of primary rat mammary carcinoma: inhibition by ethylenedinitrilotetraacetic acid but not by [ethylenebis(oxyethylenenitrilo)]tetraacetic acid. (1986) (3)
Effect of Leucogenenol on Formation of 19S and 7S Hemolysin in Normal and Splenectomized Rats 1 (1972) (3)
The first component of guinea pig complement: hemolytic assays with EA, EAC4 and with rat and guinea pig late acting components. (1971) (3)
Tissue Damage Caused by the Direct and Indirect Action of Complement (1983) (3)
IgG Behaves Like IgM Immunoglobulin in the Presence of Protein A (1978) (2)
Effect of hormones on the killing by antibody and complement of tumor cells treated with proteolytic enzymes. (1979) (2)
Guinea pig tumor-specific natural antibodies in normal rabbit sera. (1974) (2)
Complement inhibitor(s) released by leukocytes. I. Pretreatment of sheep erythrocytes with supernatants of mouse spleen and thymus cells inhibit whole complement activity and C2 utilization. (1975) (2)
Serotherapy of cancer: Cellular changes in primary rat mammary carcinomas after infusion of syngeneic sera absorbed with protein a‐sepharose (1988) (2)
Studies on the Interaction between Protein A and Immunoglobulin G (1978) (2)
Antigenic relationship between the fourth component of human and guinea pig complement. (1970) (2)
Accelerated development of benzo(alpha)pyrene-induced skin tumors in mice treated with pyran copolymer. (1974) (1)
Antigenic distinction between human C9 and guinea pig C9. (1979) (1)
Comparison of ultrafine atmospheric aerosols in Prague and Budapest 11 (2010) (1)
Abstracts of Papers Presented at the Third International Complement Workshop, Harvard Medical School, Boston, Massachusetts, June 3–5, 1968 Functional Differences Among C′4 Sites on Cell Surfaces (1968) (1)
Abstracts of Papers Presented at the Third International Complement Workshop, Harvard Medical School, Boston, Massachusetts, June 3–5, 1968 Synthesis of the First Component of Human Complement (C′1Hu), In Vitro (1968) (1)
Binding and activation of hemolytic complement by IgG antibodies: cooperativity between antibodies of different hapten specificity. (1985) (1)
Purification of the First Component (C′1) of Complement by Zonal Ultracentrifugation and of the Second (C′2) by Electrofocusing (1969) (1)
Deviated lysis (d.l.): III. Kinetics of interaction of d.l. activity with chicken erythrocytes: evidence for E formation. (1977) (1)
Differences in the functional activity of human and guinea pig C1 based on their reactivity with IgG at low temperature. (1981) (1)
The Development of the “One-Hit” or “Single Site” Theory of Complement Mediated Immune Hemolysis (2004) (1)
Increased susceptibility of tumor cells and chicken erythrocytes to lysis by antibody and complement after treatment with aminoethylisothiouronium bromide hydrobromide (AET). (1978) (1)
Augmentation of hemolytic efficiency of anti-hapten IgG antibody by anti-IgG antibody is primarily the function of the anti-hapten IgG. (1987) (1)
Mouse monoclonal antibodies at the red cell surface--I. Generation of EAC4 and interaction with C1. (1985) (1)
Editorial: Immune surveillance revisited. (1974) (1)
Studies on the Second Component of Complement (1961) (1)
Action of the First Component of Complement (1964) (1)
Biochemistry of the acute allergic reactions: Edited by K.F. Austen and E.L. Becker. Davis, Philadelphia, Penna. 1968. 352 pp., $12.00 (1969) (1)
Detection of antigens and haptens by inhibition of passive immune hemolysis. (1981) (1)
Effect of Lipids on the Cytolytic Action of Complement (C) (1978) (1)
Stimulation of Synthesis and Release of Lipids in Tumor Cells Under Attack by Antibody Plus Complement (1978) (1)
Advances in Immunity and Cancer Therapy (1986) (1)
Spontaneous and serum-induced cellular reaction in rat mammary tumours (1987) (0)
Action of a Phospholipase C Preparation on the First Component of Complement of Guinea Pig and Human Serum: Lack of Correlation with Enzyme Activity (1972) (0)
Mechanism of the Damage‐Producing Steps of Immune Haemolysis (2008) (0)
Section B. complement (1968) (0)
Anti-IgM antibody decreases dissociability of cell bound IgM anti-hapten antibodies as measured with fluid phase hapten. (1987) (0)
Histories and mysteries about C1. (1989) (0)
Mechanism of Activation of C1 by Trypsin (1973) (0)
Effect of InhibitingDNA, RNA, and Protein Synthesisof Tumor Cells on Their Susceptibilityto Killingby Antibodyand Complement (1977) (0)
Adenovirus type-7 T antigen: separation from hexon antigen by gel filtration. A preliminary report. (1968) (0)
Immune cytolysis measurement by electrolytic conductance: preliminary note. (1966) (0)
Formation and properties of ultrafine atmospheric aerosol in urban environments (2013) (0)
Internationales Komplement Symposion 14. und 15. Juli 1969 in Mainz (1969) (0)
Complement Inhibitor(s) Released by Leukocytes (1975) (0)
Kineticsof Hormone-inducedTumor Cell Resistanceto Killing by Antibodyand Complement1 (1977) (0)
1.ゾーン超遠心による補体第1成分(C1)の精製とelectrofocusingによる第2成分(C2)の精製(日米補体セミナー記録) (1970) (0)
Generation of chemotactic activity by immune complexes carrying clustered or nonclustered C&42horbar; sites (1973) (0)
Further evidence for dilution-dependent dissociation of C1q in human serum. (1989) (0)
Activation of the First Component of Complement (1972) (0)
Abstracts of Papers Presented at the Third International Complement Workshop, Harvard Medical School, Boston, Massachusetts, June 3–5, 1968 (1968) (0)
Activation of human C1r: Western blot analysis reveals slow and dose-dependent activation. (1988) (0)
Evidence for a T* Intermediate in the Antibody-Complement Mediated Killing of Tumor Cells (1976) (0)
Interaction of Lectins with Functionally Pure Complement Components (1978) (0)
Lysis of sheep red cells in neat autologous serum as a source of antibody and complement. (1984) (0)
Introduction: methodology for detection of antigens in preneoplastic and neoplastic tissues. (1972) (0)
Evidences for a “New” C1 Inhibitor, Factor S, Released from Leucocytes (1976) (0)
Effect of fibronectin on the haemolytic activity of complement. (1985) (0)
Lack of C4 binding by human igM during activation of the classical pathway (1982) (0)
Functional Activity of IgG Immunoglobulin G : I . Effect of Protein A on the Studies on the Interaction between Protein A and (2006) (0)
Immune cytolysis measurement by electrolytic conductance (1966) (0)
Generation of chemotactic activity by immune complexes carrying clustered or nonclustered C42 sites. (1973) (0)

This paper list is powered by the following services:

Tibor Borsós's Academic­Influence.com Rankings

Why Is Tibor Borsós Influential?

Tibor Borsós's Published Works

Published Works

Tibor Borsós's AcademicInfluence.com Rankings